Inverness and Thermo Fisher extend distribution deal
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations and Thermo Fisher Scientific have extended an existing distribution agreement for cardiology products until December 2010. The partnership sees Thermo (Waltham, Massachusetts) receive co-exclusivity to distribute all cardiology and drugs-of-abuse (DOA) rapid test products from the Triage brand developed by Inverness’ subsidiary Biosite. This includes tests for BNP, troponin, CK-MB, myoglobin and d-dimer, as well as meter and visually-read DOA tests. Financial terms of the deal extension were not revealed.